|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Sarissa Capital will not tender at current price
Levi & Korsinsky is investigating the Board of Directors of Astex Pharmaceuticals, Inc.
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Astex Pharmaceuticals, Inc.
The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Astex Pharmaceuticals, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating the acquisition of Astex Pharmaceuticals, Inc.
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc.
Newman Ferrara LLP is investigating potential claims against the board of directors of Astex Pharmaceuticals, Inc.
Rigrodsky & Long, P.A.
Trade-Ideas LLC identified Astex Pharmaceuticals (ASTX) as a pre-market mover with heavy volume candidate
Astex to Host Analyst/Investor Conference Call Today at 8:00 a.m. ET
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Trade-Ideas LLC identified Astex Pharmaceuticals (ASTX) as a "perilous reversal" (up big yesterday but down big today) candidate
SGI-110 Phase 2 Shows Clear Activity in Patients With Acute Myeloid Leukemia
Investors in Astex Pharmaceuticals Inc saw new options begin trading this week, for the April 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.